Skip to content

BEMER in the Treatment of Pain in Fibromyalgia.

The Efficacy of the BEMER Electromagnetic Field Therapy in the Treatment of Fibromyalgia.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02310386
Acronym
Fibromyalgia
Enrollment
110
Registered
2014-12-08
Start date
2014-09-30
Completion date
2016-12-31
Last updated
2018-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Fibromyalgia, Electromagnetic field therapy, Randomized controlled trial

Brief summary

Fibromyalgia is one the most common causes of chronic pain syndromes in women. It causes considerable costs in primary health care setting as well as specialized medical care sector.Electrotherapy and exercise therapy has shown to have short-term pain relieving effects in randomized controlled trials (RCT) among fibromyalgia patients. However, there is sparse knowledge about the effects of long-term RCTs in the treatment of pain in fibromyalgia, as there are no publications about cost-effectiveness analysis of such treatments. The aim of this study is to investigate whether the BEMER electromagnetic field therapy device has beneficial long-term effects in the treatment of pain, and whether it improves fibromyalgia patients' quality of life. In addition, this study investigates whether the BEMER device treatment is cost-effective in the treatment of fibromyalgia patients.

Detailed description

The participants of this study are working age female patients from the Central Finland Health Care District, and who have been treating because of severe pain. After eligibility has been assessed by health-related questionnaire and clinical examination, the participants will be randomly assigned into the treatment or control group. Treatment group patients will receive the loan activated BEMER-care unit, while controls will receive inactivated sham BEMER-unit. All participants will use the device regularly on a daily bases over three months. After one month treatment break, the treatment group will become a control group and control group will become a treatment group according cross-over design principle. Switching the groups will take place by changing the BEMER devices during the break. Throughout the study, both participants and researchers are unaware whether the participants are using activated or inactivated BEMER-devices. The research will be carried out and coordinated by Central Finland Central Hospital, and the research project will take place between September 2014 and June 2018.

Interventions

DEVICEBEMER electromagnetic field therapy

To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.

Sponsors

Central Finland Hospital District
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of fibromyalgia * chronic persistent moderate or severe pain for more than 12 months * average minimum pain intensity of 5 in the scale of 0 to 10 during the last 7 days * age between 18 and 60 years * female gender

Exclusion criteria

* an inflammatory rheumatic disease * some other chronic pain disease as fibromyalgia * psychiatric illness * addiction to opiates * substance abuse * smoking * a person with disability * pregnancy and breast-feeding

Design outcomes

Primary

MeasureTime frameDescription
Pain and stiffnessChange from Baseline Pain and Stiffness at 3 monthsVisual Analogue Scale (VAS)

Secondary

MeasureTime frameDescription
Cost-effectivenessThree Months Before and After the Start of the InterventionQuestions about the use of drugs, visit to doctors, physiotherapy visits, and other health-care visits.
Severity of depressionChange from Baseline Severity of Depression at 3 MonthsDepression Scale (DEPS)
Quality of lifeChange from Baseline Quality of Life at 3 monthRAND-36 Questionnaire
Symptoms and functional abilityChange from Baseline Symptoms and Functional Ability at 3 monthsFibromyalgia Impact Questionnaire (FIQ)

Other

MeasureTime frameDescription
Average weekly amount of symptoms (pain, stiffness, quality of sleep, vitality)Up to 3 monthsVAS
Number of daily treatments/drugsUp to 3 monthsDiary

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026